In terms of pharmacodynamic parameters, the clinical trial confirmed DRL_TC's similarity to the EU and US reference products.
Earlier in November 2021, Laurus acquired a 26.62% stake in ImmunoACT.
According to the study, docetaxel-based treatment has improved survival rates in men with castration-sensitive prostate cancer.
In FY23, Lupin invested 7.90% of its revenue in research and development.
During the quarter under review, the company reported an EBITDA of Rs 727 crore.
Priyavrat Bhartia will take over as the new MD from June 1, 2023.
Company's profitability was impacted due to a drastic surge in its expenses.
Intellectual Property Rights for Nidelgy will be retained by Philogen.
Last month, Cipla cracked a perpetual license agreement with Novartis.
In December 2022, Biocon’s net debt reached $1.9 billion.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
